Research graph
References from Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical utility gene card for: Alagille syndrome (ALGS)
10.1038/ejhg.2013.140 · 2014 · External reference
Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification
10.1002/humu.23879 · 2019 · External reference
Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study
10.1002/hep.32761 · 2023 · External reference
Development of a novel tool to assess the impact of itching in pediatric cholestasis
10.1007/s40271-017-0266-4 · 2018 · External reference
Systematic review: the epidemiology, natural history, and burden of Alagille syndrome
10.1097/mpg.0000000000001958 · 2018 · External reference
Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience
10.1002/lt.23437 · 2012 · External reference
EASL Clinical Practice Guidelines on genetic cholestatic liver diseases
10.1016/j.jhep.2024.04.006 · 2024 · External reference
Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice
10.1074/jbc.m306370200 · 2003 · External reference
ASBT(SLC10A2): a promising target for treatment of diseases and drug discovery
10.1016/j.biopha.2020.110835 · 2020 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a Phase III, double-blind, randomised, placebo-controlled trial
10.1016/s2468-1253(24)00074-8 · 2024 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised Phase II study
10.1016/s0140-6736(21)01256-3 · 2021 · External reference
Regression-adjusted matching and double-robust methods for estimating average treatment effects in health economic evaluation
10.1007/s10742-013-0109-2 · 2013 · External reference
Maralixibat treatment response in Alagille syndrome is associated with improved health-related quality of life
10.1016/j.jpeds.2022.09.001 · 2023 · External reference
Unresolved reference
2016 · External reference
Unresolved reference
External reference
Unresolved reference
2025 · External reference
Microbiome-encoded bile acid metabolism modulates colonic transit times
10.1016/j.isci.2021.102508 · 2021 · External reference
The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice
10.1053/j.gastro.2012.09.055 · 2013 · External reference
Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency
10.1097/hep.0000000000001430 · 2026 · External reference
Serum bile acid profiling and mixed model analysis reveal biomarkers associated with pruritus reduction in maralixibat-treated patients with BSEP deficiency
10.3390/metabo12100952 · 2022 · External reference
Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study
10.1002/hep.32761 · ExternalCitation · doi-reference
Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification
10.1002/humu.23879 · ExternalCitation · doi-reference
Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience
10.1002/lt.23437 · ExternalCitation · doi-reference
Regression-adjusted matching and double-robust methods for estimating average treatment effects in health economic evaluation
10.1007/s10742-013-0109-2 · ExternalCitation · doi-reference
Development of a novel tool to assess the impact of itching in pediatric cholestasis
10.1007/s40271-017-0266-4 · ExternalCitation · doi-reference
ASBT(SLC10A2): a promising target for treatment of diseases and drug discovery
10.1016/j.biopha.2020.110835 · ExternalCitation · doi-reference
Microbiome-encoded bile acid metabolism modulates colonic transit times
10.1016/j.isci.2021.102508 · ExternalCitation · doi-reference
EASL Clinical Practice Guidelines on genetic cholestatic liver diseases
10.1016/j.jhep.2024.04.006 · ExternalCitation · doi-reference
Maralixibat treatment response in Alagille syndrome is associated with improved health-related quality of life
10.1016/j.jpeds.2022.09.001 · ExternalCitation · doi-reference
Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised Phase II study
10.1016/s0140-6736(21)01256-3 · ExternalCitation · doi-reference
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a Phase III, double-blind, randomised, placebo-controlled trial
10.1016/s2468-1253(24)00074-8 · ExternalCitation · doi-reference
Clinical utility gene card for: Alagille syndrome (ALGS)
10.1038/ejhg.2013.140 · ExternalCitation · doi-reference
The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice
10.1053/j.gastro.2012.09.055 · ExternalCitation · doi-reference
Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice
10.1074/jbc.m306370200 · ExternalCitation · doi-reference
Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency
10.1097/hep.0000000000001430 · ExternalCitation · doi-reference
Systematic review: the epidemiology, natural history, and burden of Alagille syndrome
10.1097/mpg.0000000000001958 · ExternalCitation · doi-reference
Serum bile acid profiling and mixed model analysis reveal biomarkers associated with pruritus reduction in maralixibat-treated patients with BSEP deficiency
10.3390/metabo12100952 · ExternalCitation · doi-reference
